Respiratory Infection clinical trials

Explore recruiting respiratory infection clinical trials.

Recruiting respiratory infection studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Respiratory Infection trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Randomized, double-blind, parallel-group clinical trial, compared with placebo to evaluate the efficacy and safety of three antibiotic treatment regimens for the eradication of primary P. aeruginosa infection in patients with bronchiectasis

Spain

Phase III and phase IV (Integrated) EU CTIS Study details

A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 months to < 24 months

Spain, Latvia, Poland

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Nebulized Bacteriophage Treatment in Outpatient Adult Cystic Fibrosis (CF) Subjects with Chronic Pseudomonas aeruginosa (PsA) Pulmonary Infection

Germany, Ireland, France, Czechia, Italy, Netherlands +2 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of EDP-938 in Non-hospitalized Adults with Acute Respiratory Syncytial Virus Infection who are at High Risk for Complications

Slovakia, Spain, Poland, Czechia, Netherlands, Bulgaria

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Multicenter, Randomized, Partially Blinded, Palivizumab-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of MK-1654 in Infants and Children at Increased Risk for Severe RSV Disease

Germany, Spain, Hungary, Finland, France, Norway +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Randomized, multicenter, open-label study on PREvention of respiratory SEquelae of RSV bronchiolitis in preterm babies (PRESERV)

Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

Respiratory Infection trials by city

Respiratory Infection in Toronto Respiratory Infection in Vancouver Respiratory Infection in Montreal Respiratory Infection in Calgary Respiratory Infection in Edmonton Respiratory Infection in Ottawa Respiratory Infection in Winnipeg Respiratory Infection in Quebec City Respiratory Infection in Hamilton Respiratory Infection in Kitchener Respiratory Infection in London Respiratory Infection in Halifax Respiratory Infection in New York Respiratory Infection in Los Angeles Respiratory Infection in Chicago Respiratory Infection in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease